Related Experiment Video
Updated: Jun 14, 2026
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
[Quantification of the PRAME transcripts in patients with acute myeloid leukemia]
Zhao-hui Zhu1, Jun Qian, Jiang Lin
1Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, P.R. China.
Objective:
To analyze the expression level and clinical significance of the preferentially expressed antigen of melanoma (PRAME) transcripts in patients with acute myeloid leukemia (AML).
Methods:
Real-time quantitative polymerase chain reaction with EvaGreen dye was established to detect the expression level of PRAME transcripts in the bone marrow mononuclear cells of 56 AML cases and 20 controls. The clinical association of PRAME transcripts was analyzed.
Results:
The PRAME transcripts were 0-1.46% (median 0.18%) and 0-21 618.09% (median 9.79%) in controls and AML cases, respectively (P< 0.01). Among the FAB subtypes, those with M1, M2, M3 and M4 had significantly higher level of PRAME transcripts than controls. However, those with M5 had similar level of PRAME transcripts as controls. There was a significantly negative correlation between the PRAME transcripts and cytogenetic risk groups (r= -0.438, P= 0.001). Cases in low risk had significantly higher level of PRAME transcripts than those in intermediate and high risk. Among cases with AML-M2, those with t(8;21) had significantly higher level of PRAME transcripts (135.06% -21 618.09%, median 2201.88%) than those without t(8;21)(0.14% -1696.30%, median 17.97%)(P= 0.002). In a patient with sequential samples, PRAME transcripts significantly decreased after induction therapy and significantly increased after relapse.
Conclusion:
The PRAME transcript was highly expressed in AML patients and was a favorable marker of prognosis. Quantification of PRAME transcript can be used in monitoring disease status of AML.
Insights
Preferentially expressed antigen of melanoma (PRAME) transcripts are highly expressed in acute myeloid leukemia (AML) and indicate a favorable prognosis. PRAME transcript levels can monitor AML disease status.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Context:
- Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
- Accurate prognostic markers are crucial for AML patient management.
- Preferentially expressed antigen of melanoma (PRAME) is a gene with potential roles in cancer.
Purpose:
- To investigate the expression levels of PRAME transcripts in AML patients.
- To determine the clinical significance and prognostic value of PRAME transcripts in AML.
- To evaluate PRAME transcript quantification for monitoring AML disease status.
Summary:
- Real-time quantitative PCR detected significantly higher PRAME transcript levels in AML patients (median 9.79%) compared to controls (median 0.18%).
- Elevated PRAME expression correlated with favorable FAB subtypes (M1-M4) and lower cytogenetic risk, but not M5 subtype.
- PRAME transcript levels decreased post-therapy and increased upon relapse, suggesting its utility in disease monitoring.
Impact:
- PRAME transcript expression is a significant prognostic marker in AML.
- Quantification of PRAME transcripts offers a valuable tool for monitoring treatment response and disease progression in AML patients.
- Findings contribute to personalized medicine approaches in AML management.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018